Want to buy for someone else? You can purchase a token at check out.

Overview
Goals and Outcomes
Details
Accreditations
Overview
Overview

Low-calorie sweeteners and controversy seem to go hand in hand, with some members of the media continually fueling concerns about their safety and lack of efficacy by widely broadcasting negative studies and staying tight lipped on positive results. A small but growing number of low calorie sweeteners are approved for use by regulatory bodies around the globe, including the U.S. Food and Drug Administration. Approvals are based on numerous required safety studies with post market surveillance often a stipulation of approval. Regular reviews conducted by various regulatory agencies continue to demonstrate their safety. A growing body of evidence is demonstrating how low-calorie sweeteners, as part of an otherwise healthy eating plan, can be a tool to help people meet their health and nutrition objectives. Get an update on this evidence as well as a practical perspective on this topic.

Goals and Outcomes
Goals and Learning Outcomes
The goal of this webinar is to provide an overview of the current evidence on the health concerns of excess added sugars consumption and the safety and efficacy of low calorie sweeteners in weight management to enable healthcare providers to offer research-based practical advice to people they counsel to reduce added sugars consumption. At the conclusion of this webinar participants will be able to:
  1. Discuss the current intake of added sugars in the U.S. and related health concerns
  2. Describe the differences between the FDA process for a food additive and GRAS ingredient and identify the key elements for safety review of food additives
  3. Explain the results of recent research focused on the efficacy of low calorie sweeteners in weight management.
  4. Teach people they counsel how to change their beverage choices to reduce consumption of added sugars for health/disease prevention, and weight management.
 

 
Hope Warshaw, MMSc, RD, CDE, BC-ADM, discloses that she receives consulting and speaking fees from Heartland Food Products Group.
Details
Course Details

Course Originally Released on : 10/10/2016

WEB319

Course Author

Hope Warshaw

RD, CDE, BC-ADM

Accreditations
Accreditations

NURSES
In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, CEP#13791

Accreditations imageAccreditations image

Disclaimer: Not all courses will provide California Board of Registered Nursing approval. Per California Assembly Bill No. 241, continuing education courses related to direct patient care shall address at least one or a combination of the following:(1) Examples of how implicit bias affects perceptions and treatment decisions of licensees, leading to disparities in health outcomes; or (2) Strategies to address how unintended biases in decision-making may contribute to health care disparities by shaping behavior and producing differences in medical treatment along lines of race, ethnicity, gender identity, sexual orientation, age, socioeconomic status, or other characteristics.

CEBroker
Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, New Mexico Board Of Nursing, South Carolina Board Of Nursing and West Virginia Board Of Examiners For Registered Professional Nurses
Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.

Disclosures
None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.